BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: ORKA) | Delayed: 98.53 -1.02 (1.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $99.55 | 52 Week High | $ | |||
| Open | $102.37 | 52 Week Low | $ | |||
| Day High | $102.59 | P/E | N/A | |||
| Day Low | $96.32 | EPS | $ | |||
| Volume | 286,571 | |||||
